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1. Introduction 
In 1995, the International Diabetes Federation estimated the prevalence of diabetes to be 
approximately 135 million patients worldwide. More recently in 2010, it was estimated that 
around 285 million people were diabetic and this number is predicted to reach 438 million 
by 2030, accounting for 7.7% of the population aged 20-79 (Shaw et al 2010). However, 
despite greater knowledge of the disease, approximately one-third of people with diabetes 
remain undiagnosed. Although intensive blood glucose and blood pressure control have 
reduced the risk of diabetes-associated microvascular (nephropathy, retinopathy, 
neuropathy) and macrovascular complications (atherosclerosis), diabetes remains a major 
risk factor for cardiovascular complications, cardiomyopathy, end-stage renal disease 
(ESRD), blindness and neuropathy. There is therefore an urgent need to develop more 
effective therapeutic strategies to prevent and/or halt the progression of diabetic 
complications. 
Accumulating evidence suggests that oxidative stress plays a pivotal role in the aetiology of 
diabetic complications. Many biochemical pathways associated with hyperglycaemia 
increase the production of free radicals leading to oxidative stress, including glucose auto-
oxidation, the polyol pathway, prostanoids synthesis, protein glycation and the protein 
kinase C (PKC) pathway (Giugliano et al 1996). Hyperglycaemia alters reactive oxygen 
species (ROS) production, particularly in the mitochondria, leading to increased 
intracellular ROS and activated stress-sensitive pathways such as nuclear factor κB (NFκB), 
p38 mitogen-activated protein kinase (MAPK), and the c-Jun NH2-terminal kinase/stress-
activated protein kinase (JNK/SAPK) pathways (Johansen et al 2005). Subsequently, PKC 
activity, advanced glycation end-products (AGE) and sorbitol levels increase and this can 
lead to more ROS generation in a positive regulatory feedback loop to chronically stimulate 
stress-sensitive pathways. ROS can also inflict direct damage upon cellular macromolecules 
which, in turn, result in further oxidative stress (Evans et al 2002). 
Under physiological conditions, reactive oxygen and reactive nitrogen species (RNS) are 
produced and maintained at steady-state levels within a cell (Lushchak 2011). On the other 
hand, oxidative stress arises when an imbalance occurs between the production of 
ROS/RNS and the antioxidant defences that neutralise them, shifting the balance in favour 
www.intechopen.com
 
Oxidative Stress and Diseases 
 
248 
of enhanced ROS levels. The consequence of this shift is cellular damage to biologically 
important molecules and organelles (Sies 1997). Elevations in ROS/RNS levels are mainly 
caused by an imbalance between the activity of endogenous pro-oxidant enzymes, such as 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, xanthine oxidase or the 
mitochondrial respiratory chain, and the antioxidant enzymes, such as superoxide 
dismutase (SOD), glutathione peroxidase (GPx), heme oxygenase (HO), thioredoxin (Trx) 
peroxidase/peroxiredoxin, catalase and paraoxonase (Forstermann 2008). ROS include the 
superoxide anion (O2-) and the hydroxyl radical (
OH), as well as non-radical species such 
as hydrogen peroxide (H2O2). RNS include the free radicals nitric oxide (
NO) and non-
radical species such as peroxynitrite (ONOO-) and nitrogen dioxide (NO2)(Johansen et al 
2005). In a hyperglycaemic milieu, O2- increases through the enhanced activity of enzymatic 
sources, including NADPH oxidase and xanthine oxidase, and non-enzymatic sources such 
as the mitochondrial respiratory chain, glucose autoxidation, AGE formation and activation 
of the polyol pathway. In addition, antioxidant defences are known to decrease in a 
hyperglycaemic milieu, shifting the balance away from steady-state levels of ROS towards 
an environment of oxidative stress. 
2. Oxidative stress and diabetic complications  
2.1 Diabetes-associated atherosclerosis 
Atherosclerosis is a major cause of mortality and morbidity in patients with diabetes 
(Beckman et al 2002). The buildup of fat and cholesterol along the walls of arteries is 
progressive; it thickens and hardens, forming calcium deposits, and may eventually block 
the arteries. Blockage of the arteries and/or rupture of vulnerable plaques is a common 
cause of heart attack and stroke. Diabetes has been shown to accelerate the clinical course of 
atherosclerosis in the coronary arteries (coronary artery disease, including myocardial 
infarction), lower extremities (peripheral arterial disease) and extracranial carotid arteries 
(cerebrovascular disease, including stroke) (Beckman et al 2002).  
An understanding of the underlying mechanisms that accelerate diabetes-associated 
atherosclerosis is important in the search for treatments to protect against or retard the 
progression of this disease. The abnormal metabolic state associated with diabetes, which 
includes chronic hyperglycaemia, dyslipidemia and insulin resistance can alter the 
function of multiple cell types including endothelial cells, smooth muscle cells and 
platelets. The single layer of endothelial cells that line the vessels of the circulatory 
system, provide a metabolically active interface between the blood and the underlying 
tissue to facilitate blood flow and nutrient delivery. Disruption of the integrity of the 
endothelium leads to inflammation, activation of platelets, coagulation, and thrombosis  
(Cines et al 1998). To protect against this, the endothelium synthesises important bioactive 
substances such as endothelial-derived NO (EDNO), prostaglandins, endothelin (ET) and 
angiotensin II (Ang II) that regulate blood vessel function and structure (Beckman et al 
2002). It is now known that hyperglycaemia-mediated dysregulation of these 
vasoprotective agents either enhances the intensity of oxidative stress directly or is 
affected by oxidative stress. The consequences of hyperglycaemia-driven enhanced 
ROS/RNS on the vasculature will be discussed below. 
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2.1.1 The role of ROS in diabetes-associated atherosclerosis 
Due to its vasorelaxation, anti-inflammatory and anti-proliferative properties, EDNO is 
often viewed as vasculoprotective. Diabetes is associated with an attenuation of EDNO 
bioavailability, which is lowered by either decreased formation or enhanced removal of 
NO. One way in which hyperglycaemia attenuates the level of EDNO is by blocking the 
function of endothelial NOS (eNOS) synthase in endothelial and vascular smooth muscle 
cells (De Vriese et al 2000). However, evidence now points most strongly at the prevention 
of EDNO reaching its molecular target, rather than its attenuated production as being 
critical for the loss of EDNO bioavailability in diabetes. An increase in ROS, such as O2- 
within the endothelium is one of the most significant factors known to decrease EDNO (de 
Haan & Cooper 2011). Increased O2- can reduce EDNO bioavailability due to its propensity 
to react with NO, producing the highly reactive oxidant, ONOO- (Beckman 1996). Loss of 
functional EDNO causes impaired relaxation of the vessel wall and inhibition of the 
proliferative effects of EDNO (Maritim et al 2003a). In addition, ONOO- can induce cell 
damage via lipid peroxidation, and the inactivation of enzymes and structural proteins by 
oxidation and nitration. Furthermore,  ONOO- can activate matrix metalloproteinases 
(MMPs), trigger the release of pro-apoptic factors such as cytochrome c and induce DNA 
damage (Pacher & Szabo 2006). ONOO- is also involved in oxidising tetrahydrobiopterin 
(BH4), an important cofactor of eNOS, thereby uncoupling eNOS which then produces 
O2- 
instead of EDNO (Maritim et al 2003a). 
It is also known that a reduction in NO, as evident in diabetes, stimulates endothelial 
angiotensin-converting enzyme (ACE) activity and the generation of Ang II and O2- 
(Schulman et al 2006). While EDNO inhibits the production of endothelin-1 (ET-1) which is a 
vasoconstricting peptide (Boulanger & Luscher 1990), increased Ang II can stimulate the 
endothelial cell to synthesise and release ET-1, thereby contributing to vascular smooth 
muscle dysfunction (Sasser et al 2002). A disruption in vascular smooth muscle function 
may lead to plaque destabilisation and rupture, with often fatal consequences (Beckman et 
al 2002). Since EDNO also limits inflammation by reducing leukocyte adhesion and 
migration (Chen et al 1998), lowering EDNO will also promote atherogenesis via accelerated 
pro-inflammatory pathways. Additionally, EDNO is also involved in the inhibition of 
platelet activation (Loscalzo 2001). A reduction in the bioavailability of EDNO in diabetes 
therefore potentiates platelet activation, adhesion and aggregate formation, leading to 
thrombosis. Hence, the increased presence of O2-, as seen in diabetes, limits the protective 
effects of EDNO in the vasculature leading to increased inflammation, thrombosis, plaque 
destabilisation and plaque rupture (Fig.1). 
The effects of hyperglycaemia-mediated increases in O2- levels in the mitochondria are 
numerous and mostly detrimental to the cells of the vasculature. For example, O2- has been 
shown to activate the nuclear enzyme poly(ADP-ribose) polymerase (PARP) which in turn 
leads to metabolic alterations that activate NFκB, AGE/receptor for AGE (RAGE) and the 
polyol pathways (Pacher & Szabo 2006). Upregulation of these pathways results in more O2- 
production, while NFκB activation increases the expression of many proinflammatory 
mediators, leading to endothelial dysfunction. Furthermore, it is well accepted that ROS such 
as O2- are involved in the oxidation of low-density lipoprotein (ox-LDL), which is not 
recognised by the LDL receptor and is preferentially taken up by scavenger receptors on 
macrophages, leading to foam cell formation and atherosclerotic plaques (Boullier et al 2001). 
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Finally, it is important to highlight that increased O2- via enzymatic antioxidant conversion 
(see Fig.2) gives rise to increased levels of H2O2, an important ROS implicated in pro-
inflammatory processes that are further amplified as diabetes develops (Nicolls et al 2007). 
H2O2  has also been shown to upregulate vascular cell adhesion molecule-1 (VCAM-1), an 
important adhesion molecule that aids in the migration of leukocytes from the blood into 
the tissue (Cook-Mills 2006). It is therefore clear that elevations in hyperglycaemia-mediated 
ROS lead to cellular, molecular and functional vascular alterations that initiate, mediate and 
ultimately hasten cardiovascular complications associated with diabetes. 
2.2 Diabetic cardiomyopathy 
Diabetic cardiomyopathy is considered a distinct clinical entity first recognised by Rubler et 
al. (1972) in 4 diabetic patients with congestive heart failure without evidence of 
hypertension, coronary artery disease or congenital heart disease. The Framingham study 
showed that diabetic men and women had a 2- and 5-fold greater incidence of heart failure 
respectively, even after taking into account other common risk factors such as coronary 
artery disease, age, blood pressure, weight and cholesterol (Kannel et al 1974). Diabetic 
cardiomyopathy is characterised by early diastolic dysfunction and late systolic impairment, 
and is accompanied by a wide range of structural abnormalities and pathophysiological 
impairments (Hayat et al 2004). Despite intensive investigations, the aetiology of diabetic 
cardiomyopathy remains elusive.  
2.2.1 The role of ROS in diabetic cardiomyopathy 
Hyperglycaemia is known to upregulate the production of Ang II, which is the overt 
hormone of the renin-angiotensin system (RAS). This has a profound effect on the 
myocardium given that most of the cellular components of the RAS including 
angiotensinogen, renin and the angiotensin II type I (AT1) receptor are found in myocytes 
(Fiordaliso et al 2000). Although Ang II is known to contribute to the development of 
diabetic cardiomyopathy through its hemodynamic vasoconstrictor effects and its ability to 
act as a proinflammatory mediator, it is now becoming increasingly clear that Ang II 
mediates its effects on the myocardium via its ability to enhance production of O2- (Cooper 
2004). Indeed, Privratsky et al. (2003) found that hyperglycaemia induces cardiac 
myopathies via the AT1 receptor, with activation of NADPH oxidase and increased ROS 
generation. Furthermore, O2- levels were attenuated with an ACE inhibitor (Fiordaliso et al 
2006). However, other sources of ROS generation are known to contribute to the oxidative 
stress that accompanies diabetic cardiomyopathy. For example, treatment of diabetic mice 
with allopurinol, the xanthine oxidase inhibitor, improved type 2 diabetes-induced cardiac 
dysfunction by decreasing oxidative/nitrosative stress and fibrosis (Rajesh et al 2009). 
The biochemical pathways described earlier for diabetes-associated atherosclerosis, 
including those leading to endothelial dysfunction and inflammation due to the 
overproduction of ROS, appear to play a causal role in the pathogenesis of diabetic 
cardiomyopathy (Fig.1). Several lines of evidence suggest that nitrosative stress and 
peroxynitrite-induced damage contribute to the pathogenesis of diabetic cardiomyopathies. 
In particular, Szabo et al. (2002) showed that a metalloporphyrin peroxynitrite 
decomposition catalyst, FP15, which neutralises ONOO-, ameliorates cardiovascular 
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dysfunction in STZ-induced murine models of diabetes. Treatment with FP15 prevented loss 
of endothelium-dependent relaxant ability of blood vessels and improved both diastolic and 
systolic dysfunction of the diabetic heart, supporting the concept that neutralisation of 
ONOO- can be of significant therapeutic benefit. Furthermore, hyperglycaemia-mediated 
oxidative stress has been shown to cause abnormal gene expression, altered signal 
transduction, and the activation of pathways leading to myocyte apoptosis (Cai & Kang 
2001). Myocyte death causes a loss of contractile units, compensatory hypertrophy of 
myocytes and reparative fibrosis, all characteristics of diabetic cardiomyopathy (Kang 2001). 
In a study by Frustaci et al. (2000), increased levels of nitrotyrosine were associated with 
apoptosis and necrosis of cardiac cells including myocytes, endothelial cells and fibroblasts 
in patients with diabetes, as well as in STZ-induced diabetic mice (Cai et al 2005). However, 
the mechanisms underlying hyperglycaemia-induced myocyte loss are still poorly 
understood.  
Recently, it was shown that hyperglycaemia-induced oxidative stress results in the 
activation of the hexosamine biosynthetic pathway (HBP), leading to increased O-
GlcNAcylation (endproduct of HBP) of the pro-apoptotic peptide, BAD. In this manner 
oxidative stress is linked to increased cardiac myocyte death (Rajamani & Essop 2010). Other 
known mediators of hyperglycaemia-induced cardiac cell death include AGEs (Li et al 
2007), apoptosis signal-regulating kinase 1 (ASK1) (Thandavarayan et al 2008) and 
mitochondrial dysfunction (Duncan 2011). All of these pathways appear to induce myocyte 
apoptosis via an increase in oxidative stress in the diabetic heart. Myocyte loss and myocyte 
injury are believed to contribute to systolic dysfunction due to the impairment in the ability 
of the myocardium to develop force, resulting in reduced contractility, decreased pump 
function, and decreased ejection fraction (Fang et al 2004).  
For destructive ONOO- to form within the diabetic myocardium, as detailed above, O2- 
must interact with and reduce the bioavailability of NO. Since NO is one of the most 
important regulators of myocardial function, it is not surprising that hemodynamic studies 
have indicated that endothelium-dependent vasodilatory responses are impaired in the 
diabetic milieu (Farhangkhoee et al 2006). Indeed, the bioavailability of vasodilatory NO 
was found to be reduced with the progression of diabetic cardiomyopathy (Joffe et al 1999). 
In the heart, both eNOS and inducible NOS (iNOS) are the principal producers of NO. 
Under physiological conditions, low levels of NO produced by eNOS increase diastolic 
relaxation and decrease oxygen consumption in cardiac myocytes, whereas high levels of 
NO produced by iNOS decrease the contraction of cardiac myocytes and induce apoptosis 
(Khullar et al 2010). Under pathological conditions, such as diabetes, both enzymes can 
produce highly reactive O2- and increase oxidative stress and inflammation (Razavi et al 
2005). Additionally, loss of NO bioavailability in diabetes causes endothelial cell 
dysfunction, resulting in increased permeability of the vessel wall and reduced blood flow 
through the myocardium causing tissue ischemia. In response, endothelial cells release 
growth factors, such as transforming growth factor-ǐ (TGF-ǐ), resulting in increased 
basement membrane thickening, extracellular matrix (ECM) deposition and interstitial 
fibrosis (Farhangkhoee et al 2006). 
Diabetes-mediated increases in ROS are also known to affect structural proteins pertinent to 
the integrity of the myocardium, as well as proteins that affect its function. ROS have been 
shown to cause alterations in the function of regulatory and contractile proteins such as the 
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sarcoplasmic reticulum Ca2+-ATPase and Na+-Ca2+ exchanger in the heart (Fang et al., 2004). 
This leads to diminished calcium sensitivity of proteins involved in the regulation of the 
cardiac actomyosin system, a reduction in the sarcoplasmic reticulum Ca2+-ATPase and a 
decrease in the sarcoplasmic reticulum calcium (SERCA2a) pump protein (Abe et al., 2002). 
These deficits may all contribute to impaired LV function. Indeed, abnormal diastolic and 
systolic function was normalised in streptozotocin-induced diabetic rat hearts when 
SERCA2a was overexpressed (Trost et al., 2002).  
 
Fig. 1. Roles of reactive oxygen species (ROS) in the pathophysiology of diabetic 
macrovascular complications, namely atherosclerosis and diabetic cardiomyopathy.  
2.3 Diabetic nephropathy 
Diabetic nephropathy (DN) has become a worldwide epidemic, accounting for 
approximately one third of all cases of ESRD (Rossing 2006). DN is classically defined as the 
increase in protein excretion in the urine. The early stage of DN is characterised by a small 
increase in urinary albumin excretion (microalbuminuria), while overt diabetic nephropathy 
is defined as the presence of macroalbuminuria or proteinuria (Zelmanovitz et al 2009).  
The earliest structural changes associated with diabetic nephropathy are the expansion of 
glomerular mesangial area, mesangial cell hypertrophy and thickening of the glomerular 
basement membrane (Gilbert & Cooper 1999), leading to a progressive reduction in the 
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filtration surface of the glomerulus, a process known as glomerulosclerosis (Kalant 1978). 
Furthermore, there is now compelling evidence to suggest that disruption of the 
tubulointerstitial architecture is as important, if not more important in contributing to 
kidney injury as glomerular damage (Nangaku 2004).  
Despite intensive glucose control and blockade of the RAS (Barit & Cooper 2008; Keane et al 
2006), DN continues to progress in a significant proportion of patients and often leads to 
organ failure and the need for dialysis and/or kidney transplantation. Therefore, the 
development of novel targeted therapeutics is warranted to reduce or eliminate kidney 
disease in diabetic patients. 
2.3.1 The role of ROS in diabetic nephropathy 
An upregulation of ROS in diabetes has been implicated in the pathogenesis of kidney 
injury (Forbes et al 2008). ROS activate a number of signalling pathways including PKC, p38 
MAPK, p42/p44 MAPK and the transcription factor NF-κB, which leads to the increased 
activation of growth factors such as TGF-ǐ that contribute to the pathogenesis of DN. In the 
diabetic kidney, enhanced glucose uptake occurs in many of the cell populations including 
glomerular epithelial cells, mesangial cells and proximal tubular epithelial cells, leading to 
the excessive production of intracellular ROS, making these cells particularly susceptible to 
the diabetic milieu (Forbes et al 2008). 
Sufficient evidence exists, from both clinical and pre-clinical studies, to suggest that 
oxidative stress accompanies the progression of diabetic nephropathy. Hyperglycaemia has 
been shown to increase 8-hydroxy-2’-deoxyguanosine (8-OHdG), a marker of oxidative 
mitochondrial DNA damage in diabetic rat kidneys (Kakimoto et al 2002). In this study, 
intervention by insulin treatment normalised renal 8-OHdG level  in diabetic rats, clearly 
linking the diabetic milieu and increased oxidative stress in this pre-clinical model 
(Kakimoto et al 2002). In type 2 diabetic patients, it was found that urinary 8-OHdG 
excretion was significantly higher than in healthy controls and furthermore, that this 
increase was proportional to the severity of the tubulointerstitial lesion observed in the 
kidneys of these patients (Kanauchi et al 2002). In addition, it was reported that the 24-hour 
urinary content of 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG), a product of oxidative 
DNA damage, strongly predicted the progression of DN in type 2 diabetic patients in a 5-
year follow up study (Hinokio et al 2002).  
Several studies have examined the pathways through which increased ROS may mediate its 
damaging effects on glomerular and tubular injury in the diabetic kidney. One study showed 
that ROS mediates high glucose-induced activation of PKC in mesangial cells, leading to an 
increase in TGF-ǐ expression (Studer et al 1997). Ha et al. (2002) have demonstrated that by 
inhibiting ROS with a series of antioxidants, high glucose-induced activation of NFκB and 
NFκB-dependent monocyte chemoattractant protein-1 (MCP-1) expression was inhibited in 
mesangial cells. Furthermore, increased ROS led to accelerated glomerulosclerosis through 
TGF-ǐ-mediated plasminogen activator inhibitor-1 (PAI-1) upregulation in mesangial cells 
(Jiang et al 2003b). Similarly, it was proposed that ROS mediate kidney fibrosis in renal cells 
through the upregulation of the transcription factors NFκB and activator protein-1 (AP-1), that 
in turn increase MCP-1, TGF-ǐ and PAI-1, resulting in the increased accumulation of ECM 
(Lee et al 2003). Using several disparate antioxidants, another study  found that the TGF-ǐ-
induced cellular ROS, the phosphorylation of Smad2, p38 MAPK and extracellular signal-
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regulated kinase (ERK), as well as endothelial-mesenchymal transition (EMT) were inhibited, 
further suggesting an important role for ROS in TGF-ǐ-dependent pathways in renal tubular 
epithelial cells (Rhyu et al 2005). 
3. A role for antioxidant defence in diabetic complications 
Evidence suggests that glucose alters antioxidant defences in endothelial cells (Ceriello et al 
1996) and in patients with diabetic complications such as DN (Ceriello et al 2000; 
Hodgkinson et al 2003). Fibroblasts derived from type 1 diabetic patients susceptible to 
microvascular complications were unable to upregulate their protective antioxidative 
defences after exposure to high glucose compared with skin fibroblasts from normal 
subjects, suggesting a failure of antioxidant defences in diabetic patients with nephropathy 
(Ceriello et al 1996). In addition, the concentration of the antioxidant glutathione (GSH) is 
found to decrease in a range of organs including the liver, kidney, pancreas, plasma, and red 
blood cells of chemically induced diabetic animals (Maritim et al 2003b). Given that reduced 
GSH functions as a direct free-radical scavenger and a cosubstrate for GPx activity, as well 
as a cofactor for many enzymes, reductions in this antioxidant induced by the 
hyperglycaemic environment is likely to impact on the progression of diabetic 
complications. Thus, these findings suggest that increased ROS in diabetes is not only the 
result of their increased production, as detailed in section 2, but also a consequence of 
impaired antioxidant defences.  
3.1 Glutathione peroxidase 
Pre-clinical and clinical evidence are now mounting in support of an important role for GPx 
in the protection against diseases such as atherosclerosis, both in a non-diabetic and a 
diabetic setting. The selenocysteine-containing GPx family of antioxidant enzymes 
attenuates oxidative stress by utilising GSH to reduce hydrogen and lipid peroxides to 
water and their corresponding alcohol (Fig.2). Additionally, GPx also functions to remove 
harmful ONOO-. Thus the major role for GPx in the protection against pathogenesis may 
reside in the fact that it is the only antioxidant enzyme that metabolises three major ROS, 
H2O2, lipid peroxide (LOOH) and ONOO- (Fig.2). Several isoforms of GPx have been 
identified and they are each encoded by separate genes, which vary in cellular location, 
substrate specificity and tissue-specific functions (Brigelius-Flohé 1999). 
3.1.1 Different isoforms of GPx 
GPx1, also known as cellular GPx, was first identified as an erythrocyte enzyme that 
protects haemoglobin from oxidative injury (Mills 1957). Its ubiquitous expression in almost 
all tissues, together with its abundant expression in organs such as the kidney and liver 
have meant that this isoform is one of the most well-characterised of the GPx family (Lei 
2001). GPx2 is most prominent in the gastrointestinal tract and its role is mainly to protect 
intestinal epithelium from oxidative stress (Chu et al 1997; Esworthy et al 1998). GPx3 is 
secreted by the kidney and is the main source of plasma GPx; however GPx3 is also 
expressed in other tissues, for example in the heart (Reeves & Hoffmann 2009). GPx4 
reduces phospholipid hydroperoxides (Conrad et al 2007; Thomas et al 1990) and is thought 
to play a protective role in oxidative stress-induced apoptosis, possibly through the 
mitochondrial death pathway (Nomura et al 1999; Seiler et al 2008).  
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Fig. 2. Removal of reactive oxygen species (ROS) by antioxidant defence systems. 
Superoxide radical (O2-) is generated in low levels under physiological states but its 
production is greatly enhanced under pathological situations via enzymes such as NADPH 
oxidase, xanthine oxidase and a dysfunctional mitochondrial respiratory chain. O2- is 
neutralised to water via a two-step process involving superoxide dismutase (SOD) in the 
first step, and glutathione peroxidase (GPx) or catalase in a second step. Increased 
production of O2- and/or impairment of antioxidant defence systems lead to a build-up of 
the intermediate hydrogen peroxide (H2O2). H2O2 forms the toxic oxygen species hydroxyl 
anion (OH) via Fenton biochemistry, which is highly reactive and causes lipid peroxidation 
forming lipid hydroperoxides (LOOH). The functional importance of GPx resides in its 
ability to remove H2O2 and LOOH and neutralise these to water and lipid alcohol, 
respectively. Additionally, the increase in O2- also favours the formation of peroxynitrite 
(ONOO-) which reduces the bioavailability of nitric oxide (NO). GPx also functions to 
neutralise ONOO-. 
3.1.2 GPx in diabetes-associated complications 
GPx activity is decreased in patients with type 1 diabetes, as well as in experimentally-
induced diabetic rats (Chiu et al 2005; Dominguez et al 1998), although some studies have 
shown opposite results (Maritim et al 2003b). The decrease in GPx activity may contribute to 
the progression of diabetic complications due to the build-up of ROS such as H2O2 and 
ONOO-, leading to lipid peroxidation and oxidative injury.  
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Clinical evidence has shown that diabetic patients with cardiovascular complications have 
significantly lower enzymatic antioxidant defences, including an impairment in GPx 
activity, with this defect being more pronounced in younger patients (Čolak et al 2005). GPx 
activity is also found to decrease in diabetic rats in the heart, kidney and brain, leading to 
enhanced oxidative stress and secondary organ damage (Aliciguzel et al 2003). In particular, 
glomerular expression of GPx is significantly reduced in both human and rats with diabetes 
(Chiu et al 2005). Furthermore, diabetic rats with reduced glomerular GPx expression were 
found to have more severe glomerulosclerosis and mesangial expansion (Chiu et al 2005). 
Moreover, patients with type 1 diabetes together with DN displayed a defective GPx 
defence mechanism, in contrast to patients with type 1 diabetes but without DN (Ceriello et 
al 2000). Several studies have linked selenium deficiency to a reduction in GPx mRNA 
expression and activity in the kidney together with elevated plasma glucose, albuminuria 
and glomerulosclerosis (Fujieda et al 2007; Reddi & Bollineni 2001). These changes may be 
mediated by the profibrotic growth factor, TGF-ǐ, since inhibition of TGF-ǐ with a TGF-ǐ 
neutralising antibody, abrogated the reduction in GPx activity, as well as the increase in 
lipid peroxidation, albuminuria and glomerular injury in rats fed with a selenium-deficient 
diet (Reddi & Bollineni 2001).  
Several clinical studies have linked reduced GPx1 levels with diabetes-associated 
atherogenesis (Čolak et al 2005; Hamanishi et al 2004). Polymorphisms identified within the 
GPx1 gene resulting in reduced GPx1 activity have been linked with increased intima-media 
thickness of carotid arteries and an increased risk of cardiovascular and peripheral vascular 
disease in type 2 diabetic patients (Hamanishi et al 2004). Moreover, a reduction in red 
blood cell GPx1 activity has been associated with an increased risk of cardiovascular events 
in a prospective cohort study assessing the extent of atherosclerosis (Espinola-Klein et al 
2007; Winter et al 2003), while atherosclerotic plaques of patients with carotid artery disease 
have reduced GPx1 activity (Lapenna et al 1998). These evidence, although correlative, 
suggest that GPx1 is a key enzyme for the protection of vessels against oxidative stress and 
atherogenesis, particularly in the highly pro-oxidant diabetic environment (de Haan & 
Cooper 2011).  
The roles of GPx in mediating diabetes-associated heart injury are less well understood. 
Current evidence suggest that the compensatory upregulation of antioxidant enzymes, 
including GPx1 is impaired in the heart of severely hyperglycaemic mice (Fujita et al 2005). 
More recently, GPx3 is reported to be upregulated in the heart of STZ-diabetic mice, 
suggesting that GPx3 is the major antioxidative enzyme of the heart in the cellular defence 
against oxidative stress under hyperglycaemia (Iwata et al 2006). However, these were short 
term studies of only 4 to 10 weeks of diabetes, therefore further studies are required to 
investigate whether diabetes has long term effects on the expression and/or activity of GPx3 
in the heart. 
3.1.3 The GPx1 knockout mouse: a model of enhanced intensity of oxidative stress  
GPx1 knockout (-/-) mice, generated in our laboratory (de Haan et al 1998) and by others 
(Cheng et al 1997; Esposito et al 2000; Yoshida et al 1997) have become an important 
research tool to specifically study the protective role of GPx1 in the ROS-mediated 
progression and promotion of oxidative stress-mediated injury. Most studies investigating 
the role of GPx do so by limiting selenium intake which results in non-specific reductions of 
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all selenium-dependent enzymes (Reddi & Bollineni 2001; Rosenblat & Aviram 1998). 
Furthermore, studying GPx1 knockout mice allows us to draw meaningful conclusions 
about the protective role of this isoform of the GPx family, since standard assays do not 
discriminate between different isoforms (Lewis et al 2007). This specific knockout model 
also facilitates the distinction between the contribution of GPx1, catalase (a peroxisomal 
H2O2 metabolising enzyme) and thioredoxin reductase in the peroxidation of H2O2 to water 
(de Haan & Cooper 2011). 
Forgione et al. first reported vascular functional changes in mice associated with both a 
heterozygous (Forgione et al 2002a) and homozygous deficiency of GPx1 compared to 
wildtype (WT) mice (Forgione et al 2002b). Mesenteric arterioles of GPx+/- and GPx-/- mice 
demonstrated paradoxical vasoconstriction to endothelium-dependent vasodilatory 
compounds such as acetylcholine and bradykinin, whereas WT arterioles showed dose-
dependent vasodilation. Superfusion of GPx-/- vessels with an endothelium-independent 
vasodilator, sodium nitroprusside (SNP) resulted in dose-dependent arteriolar vasodilation 
that was similar in GPx-/- and WT vessels. These results suggest that GPx-/- mice may have 
a depletion of bioavailable EDNO. Furthermore, the observed endothelial dysfunction was 
accompanied by increased nitrotyrosine levels in the endothelial layer of the vessel wall, as 
well as elevated plasma isoprostanes, indicative that lack of GPx1 leads to oxidative stress in 
this tissue. By increasing intracellular thiol pools (GSH, cysteine) in the vascular tissue of 
GPx-/- mice using (L)-2-Oxothiazolidine carboxylic acid (OTC), endothelial dysfunction and 
oxidant stress was attenuated, further indicating the importance of GPx1 in maintaining 
normal endothelial function, as well as protecting the blood vessels from oxidative injury 
(Forgione et al 2002b). 
Several isoforms of GPx are present in kidney, however GPx1 is the major isoform expressed 
in normal kidney, and accounts for >96% of the renal GPx activity (de Haan et al 1998). 
Protection against oxidative stress is therefore most likely due to lipid and H2O2 quenching 
effects of the GPx1 isoform in the kidney. Until recently, no study has directly linked GPx1 
to the protection against DN (Chew et al 2010). Our initial studies using diabetic C57Bl/6J 
GPx-/- mice, surprisingly failed to show accelerated kidney injury compared with diabetic 
WT mice (de Haan et al 2005). Furthermore, an assessment of atherosclerosis, which is only 
possible in the aortic sinus after feeding mice diets rich in fats, cholesterol and choline, failed 
to reveal a protective role for GPx1 in G57Bl/J6 GPx-/- mice (de Haan et al 2006). As 
detailed below, the importance of GPx1 in limiting diabetes-associated atherosclerosis and 
diabetic nephropathy became evident in ApoE/GPx1 double knockout (dKO) mice, a 
murine model that encompasses three important risk factors, namely hyperglycaemia, 
hyperlipidemia and enhanced intensity of oxidative stress, seen in diabetic patients. 
3.1.4 Diabetic ApoE/GPx1 double knockout mouse: a model of accelerated diabetes-
associated atherosclerosis and diabetic nephropathy 
Since the lack of GPx1 plays a major role in endothelial dysfunction (Forgione et al 2002b), 
which is known to be an important mediator of hyperglycaemia-induced atherosclerosis 
(Nakagami et al 2005),  we hypothesised that a lack of GPx1 would accelerate atherosclerosis 
in a diabetic setting. Because rodents are more resilient than humans to the development of 
diabetic atherosclerosis, in order to generate a mouse model with similar disease 
progression and aetiology, we crossed our GPx1-/- mice with ApoE-deficient mice that 
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were also on a C57/BL6 background (Lewis et al 2007). We then compared aortic lesion 
formation and atherogenic pathways in ApoE-deficient and ApoE/GPx1 dKO mice after 
these mice were rendered diabetic using the diabetogenic agent, streptozotocin (STZ). STZ 
destroys the pancreatic ǐ-islet cells, thus providing a robust model of insulin deficient 
diabetes (Wilson & Leiter 1990). 
In our study, we demonstrated that atherosclerotic lesions within the aortic sinus region, as 
well as lesions within the arch, thoracic and abdominal region were significantly increased in 
diabetic ApoE/GPx1 dKO aortas compared with diabetic ApoE-/- aortas (Lewis et al 2007). 
This increase in aortic lesions was accompanied by an increase in macrophages, Ǐ-smooth 
muscle actin (α-SMA), RAGE and various proinflammatory (VCAM-1, MCP-1) and profibrotic 
mediators (vascular endothelial growth factor (VEGF), connective tissue growth factor 
(CTGF)). Gene expression analyses also revealed a concomitant increase in RAGE, VCAM-1, 
VEGF and CTGF in diabetic dKO aortas compared with diabetic controls. Furthermore, the 
oxidative stress marker nitrotyrosine was also significantly increased in the diabetic dKO 
aortas. These findings were observed despite upregulation of other antioxidants, suggesting 
that a lack of functional GPx1 accelerates diabetes-associated atherosclerosis via upregulation 
of proinflammatory and profibrotic pathways in ApoE-/- mice. Similar results were reported 
in a separate study using ApoE/GPx1-/- dKO mice, but in this instance atherosclerosis was 
induced by high fat diet (Torzewski et al 2007). In particular, these authors demonstrated 
increased atherosclerosis in their dKO mice, which was accompanied by increased cellularity 
in atherosclerotic lesions, as well as increased nitrotyrosine levels in the aortic wall and a lower 
level of bioactive NO (Torzewski et al 2007).  
As previously discussed, diabetic GPx1-deficient mice on a C57Bl/J6 background did not 
show accelerated kidney injury. However, on examination of the kidneys of diabetic dKO 
mice, we observed increased albuminuria and renal pathological changes which included 
mesangial expansion of the glomeruli and upregulation of profibrotic (collagen I and III, 
fibronectin, TGF-ǐ) and proinflammatory mediators (VCAM-1, MCP-1) (Chew et al 2010). 
Thus, we believe that in the diabetic C57Bl/J6 GPx1-/- mice, the significance of a lack of 
GPx1 may not have been properly revealed since lipid levels were unaffected in this model 
(de Haan et al 2005). Elevated lipid levels have been shown to be critical in accelerating DN 
since clinical observation suggests that hyperlipidemia is an important contributory factor to 
the progression of diabetic renal disease (Jenkins et al 2003; Tolonen et al 2009). Importantly, 
we show enhanced staining for nitrotyrosine, which is a marker of ONOO- damage in 
diabetic ApoE/Gpx1 dKO glomeruli and tubules of the kidney compared to diabetic ApoE-
/- controls. We have therefore established a role for GPx1 in limiting and/or preventing DN 
in the pathophysiologically relevant milieu of increased lipids known to accompany 
diabetes (Chew et al 2010).  
3.2 Other antioxidant defence systems 
3.2.1 Superoxide Dismutase (SOD) 
The SOD family of enzymes catalyse the conversion of O2- into H2O2 and oxygen in the first 
step of the antioxidant pathway (Fig.2), thereby performing an important role in the 
removal of O2-. Three isoforms exists in humans, Cu/Zn-SOD (also known as SOD1), Mn-
SOD (also known as SOD2) and SOD3 with distinct cellular localisation, namely cytosolic, 
mitochondrial and extracellular, respectively.  
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Diabetes is associated with a decrease in SOD activity in most animal studies (Brocca et al 
2008; Fujita et al 2009; Fukuda et al 2010). Lowered SOD levels are reported in serum and 
urine of STZ-treated Sprague-Dawley rats (Luo et al 2010), and decreased SOD1 and SOD3 
levels are suggested to play a key role in the pathogenesis of diabetic nephropathy (Fujita et 
al 2009). Manipulations of SOD, through the use of SOD knockout mice or SOD 
overexpressing mice, have shown the importance of these enzymes in the protection against 
diabetic complications. Indeed, SOD1 knockout mice have clearly shown the importance of 
protection by SOD1 against superoxide-mediated DN. These mice demonstrated significant 
mesangial matrix expansion, renal cortical malondialdehyde content and severe 
tubulointerstitial injury compared with diabetic controls (DeRubertis et al 2007). 
Importantly, these pathological changes were attenuated in the presence of the SOD-
mimetic, tempol (discussed in more detail in section 4.3.2). The significance of SOD2 was 
revealed in eMnSOD-Tg mice where the overexpression of mitochondrial-specific SOD 
targeted to the endothelium prevented diabetic retinopathy (Goto et al 2008). Furthermore, 
the targeted overexpression of Mn-SOD significantly attenuated morphological changes in 
diabetic hearts and improved contractility in diabetic cardiomyocytes (Shen et al 2006). 
Collectively, these studies show that targeted removal of O2-, leads to improved outcomes 
in diabetic nephropathy and retinopathy. 
3.2.2 Catalase  
Catalase is present mainly in the peroxisomes of mammalian cells as a tetrameric enzyme of 
four identically arranged subunits; each containing a heme group and NADPH at its active 
centre (MatÉs et al 1999). Similar to GPx1, the enzyme neutralise H2O2 to water and oxygen 
(Fig.2). A role for catalase in the protection against atherosclerosis comes from the analysis 
of mice overexpressing catalase. In these experiments, overexpression of catalase 
significantly reduced the severity of lesions in ApoE-deficient mice (Yang et al 2004). 
However, the role of catalase in diabetes is debatable; studies have shown that onset and 
progression of diabetes is accompanied by reductions in catalase activity (Ali & Agha 2009; 
Kamboj et al 2010; Pari et al 2010; Patel et al 2009), while others report an increase in the 
activity of catalase (Kakkar et al 1996; Kesavulu et al 2000).  
More recently, mutations within the catalase gene have been suggested to contribute to the 
increased risk of diabetes (Góth & Eaton 2000). However, other studies report no such 
association with catalase gene polymorphisms and the development of diabetic 
complications (Letonja et al 2011; Panduru et al 2010). For example, one study reported that 
blood catalase activity was lowered due to the downregulation of catalase synthesis, rather 
than specific catalase gene mutations in type 2 diabetic patients. This was also associated 
with increased H2O2 levels and dysfunctional insulin receptor signalling (Góth 2008).  
3.2.3 Thioredoxin system 
The mammalian Trx system is ubiquitously expressed and consists of Trx, Trx reductase and 
NADPH. The antioxidant properties of Trx is exerted mostly through the antioxidant 
enzymes, Trx peroxidase (also known as peroxiredoxin), which uses sulfhydryl (SH) groups 
as reducing equivalents (Chae et al., 1994). Trx reduces oxidised peroxiredoxin, which then 
scavenges H2O2 to produce water (Kang et al., 1998), thus attenuating oxidative stress in 
cells. The role of the Trx system in diabetic complications has gained considerable interest 
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since thioredoxin-interacting protein (Txnip), which is an inhibitor of Trx activity, was 
discovered to be a highly upregulated hyperglycaemia-induced gene in both human and 
animal studies (Kobayashi et al 2003; Qi et al 2007; Shalev et al 2002). Txnip directly binds to 
the catalytic active site of Trx, thus inhibiting the reducing activity of Trx (Nishiyama et al 
1999). 
In vitro studies have shown Txnip expression to be significantly upregulated by glucose in 
mesangial cells (Kobayashi et al 2003), proximal tubule cells (Qi et al 2007) and distal 
tubule/collecting duct cells (Advani et al 2009; Kobayashi et al 2003). Overexpression of Txnip 
in STZ-treated diabetic rats was associated with an increase in ROS, as well as ECM 
accumulation in the kidney (Kobayashi et al 2003; Tan et al 2011). By reducing Txnip gene 
transcription with siRNA in kidney cells, high glucose-mediated increases in ROS production 
and ECM accumulation were attenuated, together with a restoration of Trx activity (Advani et 
al 2009). These results clearly delineate a role for Trx in maintaining redox homeostasis and 
highlight the importance of Txnip dysregulation in diabetic complications. 
Txnip also plays an important role as a biomechanical effector of atherosclerosis (World et al 
2006). In the endothelium of intact rabbit aorta, exposure to physiological fluid shear stress 
decreased Txnip expression and increased Trx activity, leading to a reduction in pro-
inflammatory events mediated by the tumour necrosis factor (TNF)-ASK-1-JNK/p38 
pathway, in association with a decrease in TNF-mediated VCAM1 expression (Yamawaki et 
al 2005). Furthermore, a calcium channel blocker promoted cardiac myocyte survival and 
improved cardiac function by reducing cardiac Txnip expression, suggesting a role for 
Txnip in mediating cardiac myocyte apoptosis in diabetic cardiomyopathy (Chen et al 2009). 
4. Novel antioxidants to limit diabetic micro- and macrovascular disease 
4.1 GPx1-mimetic ebselen 
Ebselen (2-phenyl-1,2-benzisoselenazol-3[2H]-one) is a synthetic, lipid soluble, non-toxic 
seleno-organic compound (Sies & Masumoto 1997) with anti-inflammatory and antioxidant 
activities (Muller et al 1984). Ebselen eliminates hydroperoxides, including H2O2 and lipid 
peroxides due to its GPx mimetic activity (Maiorino et al 1988; Parnham et al 1987; Safayhi 
et al 1985). Additionally, ebselen also scavenges other ROS such as peroxyl radicals and 
ONOO- (Sies & Masumoto 1997). Several enzymes involved in inflammatory processes, 
including 5-lipoxygenases, NOS, NADPH oxidase, PKC and ATPase are also inhibited by 
ebselen (Sies & Masumoto 1997). Importantly, ebselen has shown tremendous potential in 
reducing injury in various experimental models. Ebselen conferred protection against 
endothelial dysfunction in stroke-prone hypertensive rats (Sui et al 2005) and improved 
cardiac function in a model of chronic iron overload (Davis & Bartfay 2004). Furthermore, 
ebselen  partially restored endothelial dysfunction in Zucker diabetic rats (Brodsky et al 
2004). Additionally, arterial lesions were reduced by ebselen in a superoxide-driven non-
inflammatory transgenic murine model, suggesting a role for ebselen in reducing 
atherosclerosis (Khatri et al 2004). Importantly, in a clinical trial, ebselen has shown 
improved neurological outcomes in patients after cerebral infarction (Yamaguchi et al 1998) 
and a safety and pharmacokinetic profile of ebselen has been established in normal 
volunteers in a Phase I trial to determine whether ebselen is protective against noise-
induced hearing loss (Lynch & Kil 2009). 
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4.1.1 Ebselen in experimental models of diabetes associated atherosclerosis and 
nephropathy 
We hypothesised that ebselen, in its capacity to act as a mimetic of GPx, would attenuate 
oxidative stress and lessen diabetes-associated atherosclerosis (Chew et al 2009). Eight 
week-old male C57Bl/J6 ApoE-/- mice were rendered diabetic with STZ and assigned to 
ebselen-gavaged and non-gavaged groups. Ebselen was administered twice daily at 
10mg/kg/day body weight starting at 10 weeks of age and continued for 20 weeks. Our 
analysis showed that ebselen reduced lesion formation in most regions of the aorta 
including the arch, thoracic and abdominal regions of diabetic ApoE-/- mice. In addition, 
ebselen attenuated aortic nitrotyrosine levels and the expression of the Nox2 subunit of 
NADPH oxidase. The cellularity of the aorta associated with a pro-atherosclerotic 
phenotype (increased Ǐ-SMA-positive cells and increased macrophage infiltration) was also 
decreased by ebselen, together with a reduction in the aortic expression of the pro-
atherosclerotic mediators, RAGE and VEGF (Chew et al 2009). These data support the 
notion of Blankenberg et al. (2003) that bolstering GPx-like activity reduces atherosclerosis. 
Furthermore, similar results were observed in our diabetic ApoE/GPx1 dKO mice where 
ebselen significantly reduced total aortic plaque, as well as regional plaque (arch, thoracic 
and abdominal) (Chew et al 2010). These reductions in plaque were also accompanied by a 
decrease in vascular oxidative stress (aortic 4-hydroxynonenal (HNE), nitrotyrosine, the 
Nox2 subunit of NADPH oxidase), as well as reductions in plasma hydroperoxides and 
urinary 8-isoprostanes. Additionally, the pro-inflammatory and pro-atherogenic mediators 
VCAM-1, MCP-1, CTGF and VEGF were attenuated by ebselen in diabetic ApoE/GPx1-
deficient aortas. These data suggest that ebselen is able to replenish GPx1 activity in this 
model, thereby reducing atherosclerosis. 
As mentioned in section 3.1.4, diabetic ApoE/GPx1 dKO mice demonstrated significant 
renal injury with an increase in albuminuria, hyperfiltration, mesangial expansion, oxidative 
stress (nitrotyrosine), pro-fibrotic (TGF-ǐ, CTGF, collagen I, III and IV, fibronectin) and pro-
inflammatory mediators (MCP-1, VCAM-1 and TNF-α) (Chew et al 2010). Ebselen 
significantly attenuated all of these parameters in diabetic dKO kidneys (Chew et al 2010). 
Our results are in agreement with Chander et al. (2004) where ebselen improved renal 
function and attenuated structural defects such as glomerulosclerosis, tubulointerstitial 
fibrosis and vasculopathy in the Zucker diabetic fat rat. Moreover, ebselen prevented the 
accumulation of lipid peroxidation products and 3-nitrotyrosine-modified proteins, and 
restored renal tissue levels of GSH (Chander et al 2004). 
4.1.2 Mechanistic understanding of the actions of ebselen 
Ebselen is well-characterised for its ability to act as a GPx mimic and can be catalytically 
maintained at the expense of GSH (Muller et al 1984; Sies & Masumoto 1997). Ebselen has 
been shown to reduce oxidative stress in several in vivo models; however this protective 
effect is unlikely to be solely due to the direct pro-oxidant interception by ebselen. Recently, 
ebselen has been reported to be an inducer of NF-E2-Related Factor 2- (Nrf-2)-dependent 
gene activation (Tamasi et al 2004). Nrf-2 is a member of the Cap’n’Collar family of basic 
region-leucine zipper (bZIP) transcription factors (Chui et al 1995). Genes upregulated by 
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Nrf-2 can be broadly classified into three separate classes; those that are involved in GSH 
synthesis (cystine membrane transporters), detoxication enzymes (rat glutathione S-
transferase A2, a non-selenium-dependent glutathione peroxidase, and NAD(P)H:quinine 
oxidoreductase), and those directly involved in the amelioration of oxidative stress (heme 
oxygenase-1 (HO-1), peroxiredoxin MSP23, and Trx reductase) (Tamasi et al 2004). Tamasi 
et al. (2004) showed that ebselen can directly induce Nrf-2-dependent gene transcription, 
including the increase of intracellular GSH production, which acts as a substrate for GPx 
activity. These data showed that the activation of Nrf-2-dependent signalling by ebselen 
could indirectly augment cellular defences, independent of the direct interception of ROS by 
ebselen. 
To further elucidate the mechanistic actions of ebselen observed in our diabetic experimental 
models, we examined the effect of ebselen on various signalling pathways implicated in 
atherosclerosis and nephropathy in human aortic endothelial cells (HAEC) (Chew et al 2009) 
and normal rat kidney (NRK) cells (Chew et al 2010). Pre-treatment of HAEC with 0.03 µM 
ebselen prior to exposure to 100 µM H2O2 reduced the H2O2-mediated increase in IkB-kinase 
(IKK) phosphorylation on critical activatory residues. Since IKK is a key regulator of NK-κB 
activation (Schmid & Birbach 2008), it is anticipated that by reducing IKK phosphorylation, 
ebselen anchors NF-κB in the cytoplasm thereby preventing the activation of pro-
inflammatory genes. We further showed that ebselen reduced the H2O2-mediated increase in 
Nox2 expression; Nox2 is known to be regulated by NK-κB (Anrather et al 2006), further 
confirming the view that ebselen affects downstream targets of NF-κB. 
The cytokine TNF-Ǐ is an important diabetes-associated pro-inflammatory mediator and is 
involved in the activation of NF-κB (Hacker & Karin 2006). Our in vitro data showed that 
H2O2-induced upregulation of TNF-Ǐ was reduced by ebselen. Our results support previous 
findings that ebselen inhibits TNF-Ǐ-induced pro-inflammatory responses in endothelial 
cells (Yoshizumi et al 2004) and other cell types (Sharma et al 2008; Tewari et al 2009). We 
also investigated the effects of ebselen on H2O2-mediated phosphorylation of JNK, a kinase 
involved in the activation of the transcription factor, AP-1. Our in vitro analysis showed that 
ebselen effectively attenuated H2O2-mediated phosphorylation of JNK, an important finding 
since phosphorylated JNK has been implicated in TNF-Ǐ-mediated endothelial activation 
(Min & Pober 1997) in particular through the interaction of AP-1 and NF-κB (Read et al 
1997). Collectively, our results with ebselen have implications not only for inflammatory 
genes known to be regulated by these pathways, but also on the proatherosclerotic pathway 
itself, since inflammatory events are integrally linked with the development and 
progression of atherosclerosis. 
Our in vitro studies in NRK cells further strengthen the notion that ebselen downregulates 
proinflammatory pathways in renal cells (Chew et al 2010). Similar to what we observed in 
HAEC, ebselen attenuated the phosphorylation of the pro-inflammatory mediator, IKK. 
Furthermore, stress-response kinases such as JNK and p38 MAPK phosphorylation were 
also attenuated by ebselen in NRK cells (Chew et al 2010). 
4.2 Novel GPx1-mimetics 
Novel GPx-mimetics, synthesised for their greater solubility and efficacy than ebselen are 
now available. Several laboratories have reported the synthesis and characterisation of novel 
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small selenium compounds as functional mimics of GPx, either by modifying the basic 
structure of ebselen or by incorporating some structural features of the native enzyme 
(Alberto et al 2010; Back 2009; Bhabak & Mugesh 2010). These synthetic mimics can be 
classified into three major categories: (i) cyclic selenenyl amides having a Se-N bond, (ii) 
diaryl diselenides, and (iii) aromatic or aliphatic monoselenides (Bhabak & Mugesh 2010). 
The most widely studied among the novel GPx-mimetics is diphenyl selenide.  
In addition to their GPx-like activity, the antioxidant activity of diphenyl diselenides may 
also be attributed to their capacity to be a substrate for mammalian Trx reductase (De Freitas 
et al 2010). In a study where acidosis was used to mediate oxidative stress in rat kidney 
homogenates, diphenyl diselenide significantly protected against lipid peroxidation, whilst 
the protection afforded by ebselen was only minor (Hassan et al 2009). Furthermore, 
diphenyl diselenide was also effective in protecting against acute renal failure induced by 
glycerol in rats (Brandão et al 2009). In cholesterol-fed rabbits, where animals exhibited 
hypercholesterolaemia and oxidative stress, diphenyl diselenide significantly reduced both 
of these risk factors of coronary artery disease in these animals (De Bem et al 2009). More 
recently, diphenyl diselenide has also been reported to attenuate atherosclerotic lesions in 
LDLr-/- mice by lowering oxidative stress and inflammation (Hort et al 2011).  
The clinical benefits of ebselen and/or these novel GPx-mimetics in attenuating diabetes-
associated complications are yet to be reported. Our pre-clinical assessments, as well as 
those of others, have highlighted the attractiveness of this class of therapeutic for their 
clinical use to prevent or attenuate both diabetes-associated atherosclerosis and DN, two co-
morbidities often present in diabetic patients. 
4.3 Other novel antioxidants 
4.3.1 NOX inhibitors 
Increased NADPH oxidase (NOX) activity, which catalyses the production of ROS, has been 
implicated in the pathogenesis of diabetic complications (Kakehi & Yabe-Nishimura 2008). 
NOX4 has been shown to not only mediate the increase in ROS, but also activate profibrotic 
pathways in type 2 DN (Sedeek et al 2010). Additionally, inhibition of NOX1 suppresses 
neointimal formation in the prevention of vascular complications associated with diabetes 
(Lee et al 2009). 
Several small molecule and peptide inhibitors of the NOX enzymes have been developed 
and are showing promise in experimental studies, but issues of specificity, potency and 
toxicity militate against any of the existing compounds as candidates for drug development 
(Kim et al 2011; Williams & Griendling 2007). In a recent study, apocynin, a proven NADPH 
oxidase inhibitor, attenuated albuminuria, improved kidney structure (glomerular and 
mesangial expansion) and reduced oxidative stress (urinary 8-OHdG and malondialdehyde) 
in aged Otsuka Long Evans Tokushima Fatty (OLETF) rats (Nam et al 2009). However, 
apocynin is considered to be non-selective in its mode of action as it also targets other 
enzymes such as Rho-kinase (Heumüller et al 2008). 
One of the most specific NOX inhibitors developed so far is gp91 (ds-tat), an 18-amino acid 
peptide which interferes with NOX assembly and activation (Rey et al 2001). This peptide 
functions by mimicking the binding region of NOX2, and possibly NOX1, which interacts 
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with p47phox. In doing so, it inhibits subunit assembly, resulting in the specific inhibition of 
O2- production from NOX and not from other oxidases such as xanthine oxidase. Gp91 (ds-
tat) has shown promise in reducing vascular ROS associated with Ang II-mediated 
hypertension in mice (Rey et al 2001), as well as reducing endothelial dysfunction and 
vascular ROS in the Dahl salt-sensitive rat model (Zhou et al 2006). However, limited 
bioavailability of this peptide has hampered its usefulness as a therapeutic agent; at present, 
it can only be administered via intravenous injection (Williams & Griendling 2007). 
VAS2870 is a fairly new NOX inhibitor discovered via high-throughput screening and is 
specific for NADPH oxidase activity (ten Freyhaus et al 2006). It has been shown to 
attenuate platelet-derived growth factor (PDGF)-dependent smooth muscle cell chemotaxis 
in vitro via a mechanism that includes the complete abolition of NOX activation and ROS 
production (ten Freyhaus et al 2006).  
Only limited in vitro and in vivo data are available for these novel compounds. Further 
testing in pre-clinical models is necessary to determine if these approaches represent feasible 
therapeutic strategies for diabetic complications. 
4.3.2 SOD mimetics 
As discussed in section 3.2.1, SOD is the first line of defence against both physiological and 
pathological ROS, by catalysing the dismutation of O2- to H2O2 (Fig.2). Protective and 
beneficial effects of SOD enzymes have been demonstrated in a broad range of superoxide-
driven diseases, both pre-clinically and clinically (Muscoli et al 2003). When tested in 
humans, Orgotein (a bovine CuZn-SOD mimetic) showed promising results in acute and 
chronic conditions associated with inflammation; however, because of its non-human origin, 
the use of bovine native enzyme in the human context caused a variety of immunological 
disorders (Muscoli et al 2003). Since then, several synthetic, low-molecular weight mimetics 
of SOD have been produced with promising results in pre-clinical models. 
The most well-characterised of the SOD-mimetics is tempol (4-hydroxy-2,2,6,6,-
tetramethylpiperidine-N-oxyl). Tempol has been reported to protect animals and mammalian 
cells from cytotoxicity induced by oxygen radicals such as H2O2 and 
O2- (Mitchell et al 1990). 
One attractive attribute of tempol is its ability to penetrate cell membranes and hence react 
with ROS both intracellularly and extracellularly, as well as within important organelles such 
as the mitochondria (Simonsen et al 2009). Tempol has been shown to improve acetylcholine- 
and arachidonic acid-induced relaxation in skeletal muscle arteries and in coronary arteries 
from diabetic animals (Gao et al 2007; Xiang et al 2008). Furthermore, in an in vivo one-kidney 
one-clip hypertensive rat model, tempol improved endothelial function in small arteries 
exposed to high blood pressure (Christensen et al 2007). However, the use of tempol may be 
limited in some instances by its propensity to increase H2O2, thereby exacerbating the 
progression of disease. For instance, in an experimental model of glomerulonephritis, tempol 
increased proteinuria and crescentric glomerulonephritis with leukocyte infiltration, as well as 
accelerating mortality in the treated group (Lu et al 2010). Moreover, tempol upregulated p65-
NFκB and osteopontin in the kidney and increased H2O2 levels in the urine. In another study, 
tempol could not prevent the development of hypertension in a hypertensive rat model 
induced by inhibiting renal medullary SOD with diethyldithiocarbamic acid (Chen et al 2003). 
These results may be due to the increased formation of H2O2, as a result of the dismutation of 
O2- by tempol, causing constriction of the medullary vessels, and counteracting the 
vasodilatory actions of tempol. 
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Manganese(Il) complex with a bis(cyclohexylpyridine)-substituted macrocyclic ligand 
(M40403) is another SOD-mimetic which has high catalytic SOD activity and is chemically 
and biologically stable in vivo. Injection of M40403 into rat models of inflammation and 
ischemia-reperfusion injury protected the animals against tissue damage, possibly by 
preventing the formation of ONOO-, as well as assisting in the direct removal of O2- 
(Salvemini et al 1999). M40403 also reversed endothelial dysfunction in ApoE-/- aortas ex 
vivo by decreasing NADPH oxidase-dependent O2- levels (Jiang et al 2003a). 
4.3.3 Mitochondrially-targeted antioxidants 
The targeted delivery of antioxidants to the mitochondria is an attractive approach to 
effectively remove or attenuate pathogenic ROS produced by the mitochondria. Animal 
studies using transgenic mice over-expressing mitochondrially-targeted SOD and catalase 
have already shown the potential of this strategy, since these transgenic mice were 
associated with significant reductions in cardiac mitochondrial oxidative stress and 
improvements in left ventricular function after antiretroviral-induced cardiomyopathy 
(Kohler et al 2009). Indeed, the development of antioxidants that specifically target the 
matrix-facing inner surface of the mitochondrial membrane is hypothesised to protect 
against mitochondrial oxidative damage (Ross et al 2005). Because of the high negative 
membrane potential of the inner mitochondrial membrane, antioxidants conjugated with a 
lipophilic triphenylphosphonium (TPP) cation such as mitoquinone, mitovitamin E and 
mitophenyltertbutyline accumulate in the mitochondrial matrix at concentrations several-
fold greater than cytosolic non-mitochondrially targeted antioxidants (Subramanian et al 
2010; Victor et al 2009). In particular, MitoQ, which has a TPP modification added to 
coenzyme Q is 100 times more potent than idebenone, a coenzymes Q derivative. 
Furthermore, MitoVitE (vitamin E attached to a TPP cation) is 350 times more potent than 
Trolox, a water soluble version of vitamin E, in fibroblasts from patients (Victor et al 2009). 
In vitro experiments using both mitoquinone and mitovitamin E have shown promising 
reductions in peroxide-mediated oxidant stress and apoptosis whilst maintaining 
proteasomal function in bovine aortic endothelial cells (BAEC) (Dhanasekaran et al 2004). 
Moreover, Mito-carboxy proxyl (Mito-CP), a mitochondrial-targeted SOD, significantly 
diminished glucose/glucose oxidase-induced formation of intracellular ROS and apoptosis 
in BAEC, while the "untargeted" carboxy proxyl (CP) nitroxide probe did not 
(Dhanasekaran et al 2005). Furthermore, a mitochondrial-targeted form of the Gpx1-
mimetic, MitoPeroxidase, which contains an ebselen moiety covalently linked to a TPP 
cation, decreases glucose and H2O2-mediated apoptosis in a rat basophilic leukemia cell line 
(RBL-2H3) (Filipovska et al 2005). Several studies have shown the accumulation of these 
compounds in the mitochondria of various tissues including brain, heart, liver and kidney, 
in mice fed mitrochondrially-targeted antioxidant compounds for several weeks (Smith et al 
1999). However, to date, their therapeutic potential in militating against diabetic 
complications has not been explored. 
4.3.4 Bolstering antioxidant defences via the transcription factor Nrf2 
Nrf2 is a redox sensitive transcription factor which regulates the expression of important 
cytoprotective enzymes (Kensler et al 2007). Nrf2 plays an important role in endogenous 
defence against sustained oxidative stress by upregulating important detoxifying phase II 
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enzymes, such as NAD(P)H:quinine oxidoreductase (NQO1) and antioxidant proteins, such 
as HO-1, through an antioxidant response element (ARE)-dependent pathway. The 
protective role of Nrf2 in diabetes-mediated kidney injury has gained considerable attention 
recently. Diabetic Nrf2 knockout  mice demonstrated increased glomerular ROS production 
and greater oxidative DNA damage and renal injury compared to control mice (Jiang et al 
2010). In addition, in human renal mesangial (Jiang et al 2010) and coronary arterial 
endothelial cells (Ungvari et al 2011), high glucose induced ROS production and the 
enhanced expression of Nrf2 and its downstream genes, such as NQO1, glutathione S-
transferase (GST), glutamate-cysteine ligase catalytic (GCLC) and HO-1. These effects of 
high glucose were significantly attenuated by silencing Nrf2 expression using siRNA or 
overexpression of kelch-like ECH-associated protein (Keap-1), which is an inhibitor of Nrf2 
(Ungvari et al 2011). Furthermore, overexpression of Nrf2 inhibited the promoter activity of 
TGF-ǐ1 in a dose-dependent manner, whereas knockdown of Nrf2 by siRNA enhanced 
TGF-ǐ1 transcription and fibronectin production, suggesting that Nrf2 plays a protective 
role in attenuating diabetic nephropathy (Jiang et al 2010). 
Hyperglycaemia is associated with the increased formation of AGE and enhanced oxidative 
stress, leading to the progression of diabetic cardiovascular disease (Thomas et al 2005). It 
was recently reported that Nrf2 is activated by AGE in BAEC, resulting in the induction of 
the antioxidant genes HO-1 and NQO1, thus confirming a protective role of Nrf2 against 
oxidative stress in diabetes (He et al 2011). Furthermore, to test the protective effects of Nrf2 
under metabolic stress, which often occurs concurrently with diabetes, Nrf2-/- mice were 
subjected to high fat diet (Ungvari et al 2011). These mice failed to show significant increases 
in the gene expression of the Nrf2 downstream targets GCLC and HO-1. In addition, 
increased ROS and endothelial dysfunction was attenuated in Nrf2-/- aortas, in contrast to 
Nrf2+/+ controls, further confirming that an adaptive activation of the Nrf2/ARE pathway 
confers endothelial protection under diabetic conditions (Ungvari et al 2011). 
Nonetheless, very few studies have directly demonstrated the therapeutic potential of 
increasing Nrf2 in pre-clinical models. Oltipraz, an Nrf2 activator, significantly prevented 
the development of insulin resistance and obesity in high fat diet (HFD)-induced C57BL/6J 
mice (Yu et al 2011). Control mice fed with HFD demonstrated reduced nuclear content of 
Nrf2 in adipose tissue, which was associated with increased Keap-1 mRNA expression and 
reduced HO-1 and NQO1; all of which were attenuated with oltipraz. Moreover,  
resveratrol, which is a polyphenolic phytoalexin that occurs naturally in many plant species, 
including grapevines and berries, was shown to attenuate STZ-induced diabetic 
nephropathy in rats, through the preservation of Nrf2 mRNA and protein expression, with 
an inhibitory effect on diabetes-induced upregulation of Keap-1 in diabetic kidneys 
(Palsamy & Subramanian 2011). As mentioned earlier, ebselen can directly upregulate the 
expression of Nrf2-dependent genes, in addition to its ability to quench H2O2 (Tamasi et al 
2004). Furthermore, ebselen has been shown to modify Keap-1, thereby relieving the 
inhibitory effect of Keap-1 on Nrf2 (Sakurai et al 2006).  
A recent clinical trial using the Nrf2 activator, bardoxolone methyl, (Pergola et al 2011) has 
generated particular interest in this type of drug to lessen the burden of DN. In this double-
blind, randomized, placebo-controlled trial, bardoxolone significantly improved the 
estimated glomerular filtration rate (eGFR) in patients with type 2 diabetes and impaired 
renal function. Current interventions appear to slow the decline in renal function by less 
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than 1 ml/min/1.73 m2 per year, therefore (Brenner et al 2001), improvements with 
bardoxolone methyl of between 5-10 ml/min/1.73 m2 are seen as a major advance over 
standard therapies. These results may lead to further pre-clinical and clinical activity to 
identify additional Nrf2 activators with possibly even greater efficacy. Indeed, the strategy 
of bolstering antioxidant defences by manipulating Nrf2 may represent a new class of 
therapy with potentially major advances over conventional therapy in the treatment of 
diabetic complications such as diabetic nephropathy. 
 
Fig. 3. Novel antioxidant strategies to attenuate increased cellular ROS production and/or 
increase the activity of endogenous antioxidant defence systems in diabetes-associated 
complications. 
5. Conclusion 
Increasing evidence has implicated a role for oxidative stress in mediating diabetes-
associated complications. Despite this, very few therapies are currently available in clinical 
practice to effectively target oxidative stress and lessen the burden of diabetic complications. 
The use of vitamins in clinical trials have been mostly disappointing, showing no overall 
benefit for major cardiovascular events and in some instances, even increasing 
cardiovascular mortality (McQueen et al 2005). Failure of vitamins in the clinic may be due 
to their lack of specificity in not correctly targeting the ROS responsible for pathogenesis; 
conversely, total ablation of ROS could be detrimental as ROS are essential for basic cell 
signalling and homeostasis. Thus, the challenge for developing an effective antioxidant 
therapy for diabetes-associated complications would be to target either the production of 
specific ROS involved in diabetes-mediated injury or to eliminate ROS now appreciated to 
contribute to diabetes-associated-atherosclerosis such as hydrogen peroxide. A further 
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challenge would be the maintenance of steady-state levels of ROS important for cellular 
processes including cell signalling. This is by no means an easy task; however, as 
highlighted in this review (Fig.3), several approaches are currently being investigated in 
pre-clinical models to lower the levels of those ROS involved in pathogenesis, or to activate 
specific antioxidant defences to lessen the diabetes-driven enhanced intensity of oxidative 
stress. The ultimate aim of these investigations is the clinical translation of novel targeted 
antioxidant therapies to lessen the burden of diabetic complications. 
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